Dr Daniel Wiseman is a Senior Clinical Lecturer at the University of Manchester, and a Consultant Haematologist at the Christie NHS Foundation. He is exploring Optimer® binders as…

The selective disruption of protein-protein interactions holds potential for new drug discovery strategies. Dr Katherine Bridge is a Research Fellow at the University of York investigating the role of…

Rapid and reversible aptamer binding is helping to build new in vivo biosensors that will change the way we diagnose and treat disease. Dr Netz Arroyo is an Assistant Professor…

Life at Aptamer Group and top tips for success in Optimer binder development In this interview, we speak with Harriet Flynn, Production Manager at Aptamer Group. From starting as…

The reproducible performance and wide target range of aptamers are enabling researchers of all levels in the pursuit of better diagnostics.   Dr Mark Platt at…

Novel diagnostic platforms are bringing possibilities for improved patient care and reduced healthcare costs. We spoke with Dr Edgar Goluch, the CEO and founder of QSM Diagnostics,